AI assistant
IMPACT BIOMEDICAL INC. — Director's Dealing 2025
Apr 7, 2025
35295_dirs_2025-04-07_0c2f5f95-6bf9-4b0d-a82d-90d248d9292c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IMPACT BIOMEDICAL INC. (IBO)
CIK: 0001834105
Period of Report: 2025-04-03
Reporting Person: Chan Heng Fai Ambrose (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-04-03 | Common stock | S | 351555 | $0.495 | Disposed | 0 | Indirect |
Footnotes
F1: On April 3, 2025, Alset International Limited sold 351,555 shares of the Issuer's common stock at a weighted average sale price of $0.495. This transaction was executed in multiple trades at prices ranging from $0.46 to $0.57. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F2: Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc.